Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression

Table 3 Association of NPAS2 rs6542993 with disease progression in advanced prostate cancer patients treated with ADT

Gene	SNP	Genotype	No. of patients	No. of events	5-year survival rate (%)	P ^a	HR (95% CI)	P ^b
NPAS2	rs6542993	AA	126	109	17.9		1.00
		AT	150	143	10.4		1.44 (1.09–1.90)	0.010
		TT	47	43	10.9		1.05 (0.73–1.53)	0.782
		AT/TT vs AA				0.024	1.32 (1.01–1.71)	0.039
		TT vs AA/AT				0.362	0.87 (0.62–1.22)	0.419
		Trend				0.284	1.09 (0.92–1.28)	0.339

ADT, androgen-deprivation therapy; SNP, single nucleotide polymorphism; HR, hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen
P < 0.05 are in italicsface
^aP values were calculated using the log-rank test
^bHRs were adjusted for age, PSA at ADT initiation, biopsy Gleason score, clinical stage, PSA nadir, and treatment modality

ISSN: 1475-2867